Market Place
Sourcing Support
Puma Biotechnology Presents Updated Findings from the TBCRC-022 Trial
07 Dec 2022 //
BUSINESSWIRE
Puma Biotechnology Presents Updated Findings from the PII Trial of Neratinib
27 Oct 2022 //
BUSINESSWIRE
Puma Announces Agreement with Takeda for the Development of Alisertib
21 Sep 2022 //
BUSINESSWIRE
Puma Presents Findings from the PII SUMMIT Basket Trial of Neratinib
11 Sep 2022 //
BUSINESSWIRE
Sandoz B2B Generic Neratinib Maleate Receives Approval in the U.S.
05 Jul 2022 //
FDA
Puma Bio Presents Results from Biliary Tract Cohort of PII Trial of Neratinib
04 Jun 2022 //
BUSINESSWIRE
Puma Biotechnology’s NERLYNX Updates for the Treatment of Breast Cancer
12 Jan 2022 //
BUSINESSWIRE
Puma Biotechnology Announces U.S Patent Term Extension for NERLYNX® (neratinib)
23 Nov 2021 //
BUSINESSWIRE
Puma Biotechnology to Present Neratinib Data at SABCS
19 Nov 2021 //
BUSINESSWIRE
Puma Presents Interim Results from the Phase II SUMMIT Trial of Neratinib
29 Jan 2021 //
BUSINESSWIRE
NCCN Oncology Research Program and Puma Biotechnology,Neratinib
15 Oct 2020 //
PRNEWSWIRE
Knight Therapeutics Announces Filling of Supplement for NERLYNX (neratinib)
03 Sep 2020 //
GLOBENEWSWIRE
CANbridge’s Nerlynx receives marketing approval from Taiwan FDA to treat HER2
09 Aug 2020 //
PHARMABIZ
Taiwan approves new drug for early breast cancer treatment
07 Aug 2020 //
BIOSPECTRUMASIA
CANbridge Receives Marketing Approval for NERLYNX® (neratinib) in Taiwan
06 Aug 2020 //
BUSINESSWIRE
Acentrus Specialty Partners with Puma Biotechnology to Bring Nerlynx®
21 Jul 2020 //
BUSINESSWIRE
Malaysia approves new early breast cancer drug
20 Jul 2020 //
BIOSPECTRUMASIA
New Early Breast Cancer Drug Now Approved in Malaysia
17 Jul 2020 //
PRNASIA
Malaysia approves new early Breast Cancer Drug
16 Jul 2020 //
BIOSPECTRUMASIA
Puma Licensing Partner Specialised Therapeutics Receives Marketing Approval i
16 Jul 2020 //
BUSINESSWIRE
Puma Licensing Partner Specialised Therapeutics Receives Marketing NERLYNX®
16 Jul 2020 //
BUSINESSWIRE
Puma Licensing Partner CANbridge Pharma Receives Mkt Approval China for NERLYNX®
07 May 2020 //
BUSINESSWIRE
Bixink to bring new breast cancer drug to Korea
05 May 2020 //
BIOSPECTRUMASIA
Bixink to bring new breast cancer drug to Korea
04 May 2020 //
BIOSPECTRUMASIA
Puma & Bixink Therapeutics Enter into Exclusive Agreement to NERLYNX®
30 Apr 2020 //
BUSINESSWIRE
New Early Breast Cancer Drug Available Now In Singapore
23 Apr 2020 //
PR NEWSWIR
New Early Breast Cancer Drug Available Now In Singapore
22 Apr 2020 //
PR NEWSWIRE
US FDA approves Puma`s SNDA for neratinib in combo with capecitabine
28 Feb 2020 //
PHARMABIZ
FDA Approves Supplemental NDA for Neratinib in Metastatic HER2-Positive
26 Feb 2020 //
TARGETEDONC
Puma Receives US FDA Approval of sNDA for Neratinib to Treat HER2-Positive MBC
26 Feb 2020 //
BUSINESSWIRE
BD, Babson pair up to bring capillary blood draw to pharmacies
21 Feb 2020 //
FIERCEBIOTECH
Puma Biotechnology Presents Results from the Phase II SUMMIT Trial of Neratinib
11 Dec 2019 //
BUSINESSWIRE
Singapore approves new early breast cancer drug
03 Dec 2019 //
BIOSPECTRUM ASIA
Puma Amends License Agreement with Pierre Fabre to Include Additional Countries
02 Dec 2019 //
BUSINESSWIRE
Puma Biotechnology Licensing Partner CANbridge Pharma for NERLYNX® (neratinib)
05 Nov 2019 //
BUSINESSWIRE
FDA Approves Labeling Supplement for Puma Biotechnology’s NERLYNX® (neratinib)
02 Oct 2019 //
BUSINESSWIRE
Puma Licensing Partner Pint Receives Marketing Authorization for NERLYNX®
03 Sep 2019 //
BUSINESSWIRE
FDA Grants Orphan Drug Designation to Puma Biotechnology’s NERLYNX®
03 Sep 2019 //
BUSINESSWIRE
NICE recommends Pierre Fabre`s Nerlynx in adjuvant HER2+ breast cancer
08 Aug 2019 //
PHARMAFILE
Disappointing Nerlynx sales shows Pierre Fabre timing is everything
13 May 2019 //
EVALUATE
Puma Biotech cancer launch Nerlynx suffered in Q1.
10 May 2019 //
FIERCE PHARMA
EMA Sees Spike in Medicines Recommendations in 2018
05 Jan 2019 //
RAPS
Puma Biotech Announces Top Line Results of Phase III NALA Trial of Neratinib
18 Dec 2018 //
BUSINESSWIRE
CANbridge Pharmaceutical Submits NDA for NERLYNX® (neratinib) in China
02 Oct 2018 //
BUSINESSWIRE
Puma Biotechnology`s Nerlynx (neratinib) Receives Approval in Europe
14 Sep 2018 //
EMA
EC Approves Puma`S Nerlynx As Adjuvant For Breast Cancer
04 Sep 2018 //
BIOCENTURY
CHMP reverses course on neratinib, handing Puma an unexpected win on EU Mkt vote
27 Jun 2018 //
ENDPTS
NCCN Guidelines for Central Nervous System Cancers Include NERLYNX® (neratinib)
02 Apr 2018 //
BUSINESSWIRE
Six medicines recommended for approval, including one orphan
24 Mar 2018 //
EMA
EMA’s CHMP Rejects Two Drugs Approved by US FDA in 2017
24 Mar 2018 //
RAPS
Five new medicines backed for EU approval
26 Feb 2018 //
PHARMA TIMES
Hit by an expected EMA rejection, Puma plans to appeal -ve opinion on neratinib
23 Feb 2018 //
ENDPTS
Puma touts its latest advances for Nerlynx, as EU ready to reject the drug
02 Feb 2018 //
ENDPTS
After EMA flop, Puma takes Nerlynx to China in new out-licensing deal
01 Feb 2018 //
ENDPTS
5 Biotechs Drawing Buyout Buzz in 2018
24 Jan 2018 //
BIOSPACE
